Compare Cintas Corporation (CTAS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Moderna, Inc. — how do they compare? Cintas Corporation trades at $205.78 (market cap $82.15B), while Moderna, Inc. trades at $63.62 (market cap $24.18B). The key difference: Cintas Corporation is far larger — about 3.4× Moderna, Inc.'s market cap, and Cintas Corporation pays a 1.01% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| CTAS | MRNA | |
|---|---|---|
Market Cap | $82.15B | $24.18B |
Sector | Industrials | Health |
52-Week High | $225.10 | $81.80 |
52-Week Low | $163.55 | $22.36 |
Enterprise Value | $84.56B | $20.33B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $203.51, up 0.39% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company reported strong fiscal 2026 results with revenue of $10.34 billion and net income of $1.81 billion, supported by robust profitability margins. Analyst consensus is a 'Buy' with a $225.83 price target, though valuation multiples like a P/E of 41.81 suggest premium pricing. Recent news highlights dividend declarations and institutional buying interest.
Outlook remains positive given consistent earnings outperformance and upward revenue guidance, but risks include high valuation sensitivity and economic cyclicality. The stock offers growth potential from operational efficiency and market share gains, yet investors should weigh elevated multiples against sector peers.
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
